Trial Profile
A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Lobeglitazone/metformin (Primary) ; Lobeglitazone; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 18 Mar 2017 Results of this and other study (NCT02648854), presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 07 Oct 2015 New trial record